Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
January 04, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
December 06, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be...
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
November 17, 2021 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 04, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
–On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease– – Losmapimod update planned for Q1 2022 – –Raised $144.2 million in gross...
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
November 03, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
October 28, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
September 20, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
– Presentations highlight progress in the development of losmapimod for FSHD – CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage...
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
September 08, 2021 07:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...